Literature DB >> 7565764

The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain.

A Greco1, C Mariani, C Miranda, A Lupas, S Pagliardini, M Pomati, M A Pierotti.   

Abstract

Oncogenic rearrangements of the NTRK1 gene (also designated TRKA), encoding one of the receptors for the nerve growth factor, are frequently detected in thyroid carcinomas. Such rearrangements fuse the NTRK1 tyrosine kinase domain to 5'-end sequences belonging to different genes. In previously reported studies we have demonstrated that NTRK1 oncogenic activation involves two genes, TPM3 and TPR, both localized similarly to the receptor tyrosine kinase, on the q arm of chromosome 1. Here we report the characterization of a novel NTRK1-derived thyroid oncogene, named TRK-T3. A cDNA clone, capable of transforming activity, was isolated from a transformant cell line. Sequence analysis revealed that TRK-T3 contains 1,412 nucleotides of NTRK1 preceded by 598 nucleotides belonging to a novel gene that we have named TFG (TRK-fused gene). The TRK-T3 amino acid sequence displays, within the TFG region, a coiled-coil motif that could endow the oncoprotein with the capability to form complexes. The TRK-T3 oncogene encodes a 68-kDa cytoplasmic protein reacting with NTRK1-specific antibodies. By sedimentation gradient experiments the TRK-T3 oncoprotein was shown to form, in vivo, multimeric complexes, most likely trimers or tetramers. The TFG gene is ubiquitously expressed and is located on chromosome 3. The breakpoint producing the TRK-T3 oncogene occurs within exons of both the TFG gene and the NTRK1 gene and produces a chimeric exon that undergoes alternative splicing. Molecular analysis of the NTRK1 rearranged fragments indicated that the chromosomal rearrangement is reciprocal and balanced and involves loss of a few nucleotides of germ line sequences.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7565764      PMCID: PMC230863          DOI: 10.1128/MCB.15.11.6118

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  37 in total

1.  The human minisatellite consensus at breakpoints of oncogene translocations.

Authors:  A M Krowczynska; R A Rudders; T G Krontiris
Journal:  Nucleic Acids Res       Date:  1990-03-11       Impact factor: 16.971

2.  Demonstration by in situ hybridization of ret proto-oncogene mRNA in developing placenta during mid-term of rat gestation.

Authors:  Z Szentirmay; Y Ishizaka; H Ohgaki; T Tahira; M Nagao; H Esumi
Journal:  Oncogene       Date:  1990-05       Impact factor: 9.867

3.  Mechanism of met oncogene activation.

Authors:  M Park; M Dean; C S Cooper; M Schmidt; S J O'Brien; D G Blair; G F Vande Woude
Journal:  Cell       Date:  1986-06-20       Impact factor: 41.582

4.  Molecular and biochemical characterization of the human trk proto-oncogene.

Authors:  D Martin-Zanca; R Oskam; G Mitra; T Copeland; M Barbacid
Journal:  Mol Cell Biol       Date:  1989-01       Impact factor: 4.272

5.  Amino acid preferences for specific locations at the ends of alpha helices.

Authors:  J S Richardson; D C Richardson
Journal:  Science       Date:  1988-06-17       Impact factor: 47.728

Review 6.  An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs.

Authors:  M Kozak
Journal:  Nucleic Acids Res       Date:  1987-10-26       Impact factor: 16.971

7.  A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences.

Authors:  D Martin-Zanca; S H Hughes; M Barbacid
Journal:  Nature       Date:  1986 Feb 27-Mar 5       Impact factor: 49.962

8.  The Z-DNA motif d(TG)30 promotes reception of information during gene conversion events while stimulating homologous recombination in human cells in culture.

Authors:  W P Wahls; L J Wallace; P D Moore
Journal:  Mol Cell Biol       Date:  1990-02       Impact factor: 4.272

9.  High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma.

Authors:  I Bongarzone; M A Pierotti; N Monzini; P Mondellini; G Manenti; R Donghi; S Pilotti; M Grieco; M Santoro; A Fusco
Journal:  Oncogene       Date:  1989-12       Impact factor: 9.867

10.  Alternating purine-pyrimidine tracts may promote chromosomal translocations seen in a variety of human lymphoid tumours.

Authors:  T Boehm; L Mengle-Gaw; U R Kees; N Spurr; I Lavenir; A Forster; T H Rabbitts
Journal:  EMBO J       Date:  1989-09       Impact factor: 11.598

View more
  54 in total

1.  Identifying transient protein-protein interactions in EphB2 signaling by blue native PAGE and mass spectrometry.

Authors:  Costel C Darie; Katrin Deinhardt; Guoan Zhang; Helene S Cardasis; Moses V Chao; Thomas A Neubert
Journal:  Proteomics       Date:  2011-10-28       Impact factor: 3.984

2.  The PB1 domain and the PC motif-containing region are structurally similar protein binding modules.

Authors:  Sosuke Yoshinaga; Motoyuki Kohjima; Kenji Ogura; Masashi Yokochi; Ryu Takeya; Takashi Ito; Hideki Sumimoto; Fuyuhiko Inagaki
Journal:  EMBO J       Date:  2003-10-01       Impact factor: 11.598

3.  Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma.

Authors:  Alan Charest; Vicky Kheifets; Julie Park; Keara Lane; Kevin McMahon; Cathy L Nutt; David Housman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

4.  Functional interaction between p75NTR and TrkA: the endocytic trafficking of p75NTR is driven by TrkA and regulates TrkA-mediated signalling.

Authors:  Lorena Perrone; Simona Paladino; Marialuisa Mazzone; Lucio Nitsch; Massimo Gulisano; Chiara Zurzolo
Journal:  Biochem J       Date:  2005-01-01       Impact factor: 3.857

5.  Mechanisms of activation and repression by the alternative splicing factors RBFOX1/2.

Authors:  Shuying Sun; Zuo Zhang; Oliver Fregoso; Adrian R Krainer
Journal:  RNA       Date:  2011-12-19       Impact factor: 4.942

6.  AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts.

Authors:  Radhika Iyer; Carly R Varela; Jane E Minturn; Ruth Ho; Anisha M Simpson; Jennifer E Light; Audrey E Evans; Huaqing Zhao; Kenneth Thress; Jeffrey L Brown; Garrett M Brodeur
Journal:  Cancer Chemother Pharmacol       Date:  2012-05-24       Impact factor: 3.333

7.  Novel domains in NADPH oxidase subunits, sorting nexins, and PtdIns 3-kinases: binding partners of SH3 domains?

Authors:  C P Ponting
Journal:  Protein Sci       Date:  1996-11       Impact factor: 6.725

Review 8.  Regulation of traffic and organelle architecture of the ER-Golgi interface by signal transduction.

Authors:  Kerstin D Tillmann; Valentina Millarte; Hesso Farhan
Journal:  Histochem Cell Biol       Date:  2013-07-03       Impact factor: 4.304

Review 9.  COPII-mediated trafficking at the ER/ERGIC interface.

Authors:  Jennifer Peotter; William Kasberg; Iryna Pustova; Anjon Audhya
Journal:  Traffic       Date:  2019-05-30       Impact factor: 6.215

Review 10.  TRK Inhibition: A New Tumor-Agnostic Treatment Strategy.

Authors:  Shivaani Kummar; Ulrik N Lassen
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.